Surgery and Radiation Added to Standard HER2+ Breast Cancer Treatment
Part of Cancer clinical trials.
This study tests whether adding surgery to remove the breast tumor and radiation therapy to destroy remaining cancer spots improves outcomes for people diagnosed with HER2-positive breast cancer that has already spread to a few other parts of the body. You'll receive standard chemotherapy and HER2-targeted drugs first, then be assigned to receive either additional surgery and radiation or to continue with standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- HER2-positive breast cancer that spread at diagnosis (stage IV) with 1–5 cancer spots in distant locations
- No prior history of breast cancer before this diagnosis
- At least 18 years old and able to tolerate standard cancer treatment
- Either treatment-naïve or have completed 1–3 cycles of standard HER2-targeted therapy without disease progression
- Able to receive surgery to the breast and radiation to all cancer spots, per your doctor's judgment
- If brain metastases present: 5 or fewer lesions, each smaller than 2 cm, and no previous whole-brain radiation
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study helps doctors choose the best treatment for advanced breast cancer that has stopped responding to hormone therapy. Researchers will analyze your tumor's biology to recommend a personalized treatment plan designed specifically for your cancer.
This study tests whether combining surgery or strong focused radiation with standard treatment can help people whose HER2-positive breast cancer has spread to a few spots (5 or fewer) in the body, but not the brain. It's for patients whose cancer is stable after at least 3 months of first-line therapy.
This trial tests a combination of radiation therapy, immunotherapy, and a drug that blocks blood vessel growth for advanced HER2-negative breast cancer that has spread. It is for patients whose cancer has worsened after at least two prior treatments.
This trial tests a combination of two drugs, trastuzumab deruxtecan (SHR-A1811) and pertuzumab, given before surgery to shrink HER2-positive breast cancer. It is for women with stage II or III breast cancer who have not yet had treatment and are in good overall health.
This trial aims to see if patients who had a complete response to chemo before surgery can safely stop or reduce their targeted therapy afterward. It includes people with early-stage HER2-positive or triple-negative breast cancer who had no cancer cells left in the tissue removed at surgery (a pathological complete response).
This trial tests a sequence of targeted therapy drugs for HER2-positive advanced breast cancer that has spread or cannot be removed by surgery. It aims to see if starting with trastuzumab rezetecan, followed by pyrotinib and trastuzumab plus capecitabine, helps control the cancer.
Hear when a new Anatomic Stage IV Breast Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.